172 related articles for article (PubMed ID: 21354407)
1. Induced conformational changes in the activation of the Pseudomonas aeruginosa type III toxin, ExoU.
Benson MA; Komas SM; Schmalzer KM; Casey MS; Frank DW; Feix JB
Biophys J; 2011 Mar; 100(5):1335-43. PubMed ID: 21354407
[TBL] [Abstract][Full Text] [Related]
2. Identification of superoxide dismutase as a cofactor for the pseudomonas type III toxin, ExoU.
Sato H; Feix JB; Frank DW
Biochemistry; 2006 Aug; 45(34):10368-75. PubMed ID: 16922513
[TBL] [Abstract][Full Text] [Related]
3. Cooperative Substrate-Cofactor Interactions and Membrane Localization of the Bacterial Phospholipase A
Tessmer MH; Anderson DM; Buchaklian A; Frank DW; Feix JB
J Biol Chem; 2017 Feb; 292(8):3411-3419. PubMed ID: 28069812
[TBL] [Abstract][Full Text] [Related]
4. Conformational Changes and Membrane Interaction of the Bacterial Phospholipase, ExoU: Characterization by Site-Directed Spin Labeling.
Feix JB; Kohn S; Tessmer MH; Anderson DM; Frank DW
Cell Biochem Biophys; 2019 Mar; 77(1):79-87. PubMed ID: 30047043
[TBL] [Abstract][Full Text] [Related]
5. Interactions of the effector ExoU from
Springer TI; Reid TE; Gies SL; Feix JB
J Biol Chem; 2019 Dec; 294(50):19012-19021. PubMed ID: 31662432
[No Abstract] [Full Text] [Related]
6. Activation of ExoU phospholipase activity requires specific C-terminal regions.
Schmalzer KM; Benson MA; Frank DW
J Bacteriol; 2010 Apr; 192(7):1801-12. PubMed ID: 20097856
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitin and ubiquitin-modified proteins activate the Pseudomonas aeruginosa T3SS cytotoxin, ExoU.
Anderson DM; Schmalzer KM; Sato H; Casey M; Terhune SS; Haas AL; Feix JB; Frank DW
Mol Microbiol; 2011 Dec; 82(6):1454-67. PubMed ID: 22040088
[TBL] [Abstract][Full Text] [Related]
8. Role of the membrane localization domain of the Pseudomonas aeruginosa effector protein ExoU in cytotoxicity.
Veesenmeyer JL; Howell H; Halavaty AS; Ahrens S; Anderson WF; Hauser AR
Infect Immun; 2010 Aug; 78(8):3346-57. PubMed ID: 20479080
[TBL] [Abstract][Full Text] [Related]
9. Structural basis of cytotoxicity mediated by the type III secretion toxin ExoU from Pseudomonas aeruginosa.
Gendrin C; Contreras-Martel C; Bouillot S; Elsen S; Lemaire D; Skoufias DA; Huber P; Attree I; Dessen A
PLoS Pathog; 2012; 8(4):e1002637. PubMed ID: 22496657
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the ExoU activation mechanism using EPR and integrative modeling.
Tessmer MH; DeCero SA; Del Alamo D; Riegert MO; Meiler J; Frank DW; Feix JB
Sci Rep; 2020 Nov; 10(1):19700. PubMed ID: 33184362
[TBL] [Abstract][Full Text] [Related]
11. Pseudomonas aeruginosa causes acute lung injury via the catalytic activity of the patatin-like phospholipase domain of ExoU.
Pankhaniya RR; Tamura M; Allmond LR; Moriyama K; Ajayi T; Wiener-Kronish JP; Sawa T
Crit Care Med; 2004 Nov; 32(11):2293-9. PubMed ID: 15640644
[TBL] [Abstract][Full Text] [Related]
12. Intoxication of host cells by the T3SS phospholipase ExoU: PI(4,5)P2-associated, cytoskeletal collapse and late phase membrane blebbing.
Sato H; Frank DW
PLoS One; 2014; 9(7):e103127. PubMed ID: 25061861
[TBL] [Abstract][Full Text] [Related]
13. Identification of the major ubiquitin-binding domain of the Pseudomonas aeruginosa ExoU A2 phospholipase.
Anderson DM; Feix JB; Monroe AL; Peterson FC; Volkman BF; Haas AL; Frank DW
J Biol Chem; 2013 Sep; 288(37):26741-52. PubMed ID: 23908356
[TBL] [Abstract][Full Text] [Related]
14. In vivo phospholipase activity of the Pseudomonas aeruginosa cytotoxin ExoU and protection of mammalian cells with phospholipase A2 inhibitors.
Phillips RM; Six DA; Dennis EA; Ghosh P
J Biol Chem; 2003 Oct; 278(42):41326-32. PubMed ID: 12915403
[TBL] [Abstract][Full Text] [Related]
15. Identification of a ubiquitin-binding interface using Rosetta and DEER.
Tessmer MH; Anderson DM; Pickrum AM; Riegert MO; Moretti R; Meiler J; Feix JB; Frank DW
Proc Natl Acad Sci U S A; 2018 Jan; 115(3):525-530. PubMed ID: 29295930
[TBL] [Abstract][Full Text] [Related]
16. Lysophospholipase A activity of Pseudomonas aeruginosa type III secretory toxin ExoU.
Tamura M; Ajayi T; Allmond LR; Moriyama K; Wiener-Kronish JP; Sawa T
Biochem Biophys Res Commun; 2004 Apr; 316(2):323-31. PubMed ID: 15020221
[TBL] [Abstract][Full Text] [Related]
17. The mechanism of action of the Pseudomonas aeruginosa-encoded type III cytotoxin, ExoU.
Sato H; Frank DW; Hillard CJ; Feix JB; Pankhaniya RR; Moriyama K; Finck-Barbançon V; Buchaklian A; Lei M; Long RM; Wiener-Kronish J; Sawa T
EMBO J; 2003 Jun; 22(12):2959-69. PubMed ID: 12805211
[TBL] [Abstract][Full Text] [Related]
18. ExoU is a potent intracellular phospholipase.
Sato H; Frank DW
Mol Microbiol; 2004 Sep; 53(5):1279-90. PubMed ID: 15387809
[TBL] [Abstract][Full Text] [Related]
19. Association between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a review.
Sawa T; Shimizu M; Moriyama K; Wiener-Kronish JP
Crit Care; 2014 Dec; 18(6):668. PubMed ID: 25672496
[TBL] [Abstract][Full Text] [Related]
20. A C-terminal domain targets the Pseudomonas aeruginosa cytotoxin ExoU to the plasma membrane of host cells.
Rabin SD; Veesenmeyer JL; Bieging KT; Hauser AR
Infect Immun; 2006 May; 74(5):2552-61. PubMed ID: 16622190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
